Kinase Activity Profiling
Providing comprehensive solutions

PamGene’s PamChip arrays are used to measure the activity of kinases in lysates obtained from cell lines, xenograft and tumor biopsies using arrays with immobilized tyrosine or serine/threonine peptide substrates. The technology has been successfully applied in many areas, with exciting results, as illustrated below.
Biochemical characterization Target Discovery Target identification
Pathway Elucidation Biomarker Identification Biomarker Discovery

 

We offer Services in the framework of a Service Contract, in various research areas, tailored to your interests. 

Opening up new roads, new possibilities to explore. Together! 

For advice, to find out more, initiate a discussion with us, or receive a quote, please register your details!

Download the latest Kinase activity profiling brochure!


 

Key advantages, Unique assets
  • High sensitivity! For each array between 0,5 – 5 ug of protein is sufficient to generate a kinome profile.
  • Full length proteins! Measure activities in not only recombinant kinases but a wide variety of lysates.
  • Broad protein interrogation! No a priori limitations
  • On-chip pharmacology! Directly measure inhibition of kinase activity by inhibitor spike-in ex vivo
  • Real time kinetics! Filter for high quality information with less noise

 

Biochemical characterization Target Discovery Target Interaction
Kinase enzymology, Substrate identification for novel, mutated or post-translationally modified kinases Discovery of novel targets using cell lines, xenografts and clinical tissues (as no a priori  target information is required) Reveal target interaction or engagement to develop (surrogate) PD-markers or in mechanistic studies 
 

Identification of peptide substrates for JAK2 and analysis of catalytic function

Kinetic analysis of WT JAK2 and V617F mutant kinase JH2 domains 

Kinetic characterization and Identification of substrates for PKA 

Selectivity profiling of bisubstrate-based inhibitors for isozymes of PKC

Differences in catalytic activity of BCR-ABL1 and the oncogenic NUP214-ABL1

Role of Akt in high-grade osteosarcoma cell lines and therapeutic implications

Discovery of PIM-1 as a major contributor to HIV-1 reactivation

PI3K in metastatic locally advanced rectal cancer

TrK as a novel radiation modulator inferred from PamChip data 

Identification of new possible targets for leukemia treatment

Effect of dual inhibition of Jak2 and STAT5 in myeloproliferative neoplasia 

Effect of antiangiogenic therapy in basal- and luminal-like breast cancer 

Development of selective bisubstrate-based inhibitors against PKC 

Antitumor effects of a MET/RON small-molecule inhibitor NSCLC

Novel target interactions by kinome profiling in pediatric brain tumors
     
Pathway Elucidation Biomarker Identification Biomarker Discovery
Disease pathways, resistance mechanisms, mechanism of action of small molecule inhibitors Diagnostic, Prognostic and Classification biomarker identification studies requiring small amounts of frozen archival tissues. On-chip pharmacology capabilities lend a new approach to discovering therapy-predictive biomarkers 

AKN-028 in cell cycle arrest and downregulation of Myc in CML

STAT5A in hypoxic tumor signaling in castration-resistant prostate cancer

Discovery of a transactivation mechanism of RET-FAK 

Identification of the regulatory role of PTEN in EGFR inhibitor response 

Osteoblast-induced EGFR/ERBB2 signaling in AR sensitive prostate cancer 

Biomarkers to optimize targeted therapy through systems biology approaches

Angiogenic signaling markers and early systemic dissemination in rectal cancer 

Challenges and perspectives in triple-negative breast cancer research

Semi-parametric mixed models to develop biomarkers using PamChip arrays

Differential activity of Src in primary and metastatic Uveal Melanoma

 

Temozolomide and radiation resistance in Glioblastoma multiforme xenolines 

Differential inhibition of vemurafenib in BRAF(V600E) and BRAF WT melanoma 

Prediction of response to preoperative chemoradiotherapy in rectal cancer 

Response signature for the development of a multi-targeted kinase inhibitor 

Blind prediction of response to neo-adjuvant TKI in early-stage NSCLC 

 


Contact us to share your ideas of innovative studies that can offer solutions!
Do you have more? Like we said, possibilities are endless. We just have to find them!

 

The road to discovery and innovation can be long and tough.
Let US make the difference.
Because we can.